1. Search Result
Search Result
Results for "

can increase the release of insulin

" in MedChemExpress (MCE) Product Catalog:

9

阻害剤およびアゴニスト

2

ペプチド

1

天然物

製品番号 製品名 Target 研究分野 構造式
  • HY-B1114
    Gliquidone
    2 Publications Verification

    AR-DF 26

    Potassium Channel ERK STAT NF-κB COX Interleukin Related Reactive Oxygen Species (ROS) Metabolic Disease
    Gliquidone can bind to the pancreatic β-cells and increases insulin release to regulate blood glucose levels. Gliquidone significantly decreases LPS (HY-D1056)-induced proinflammatory responses and inhibits ERK/STAT3/NF-κB phosphorylation in BV2 microglial cells. Gliquidone can suppress microgliosis, microglial hypertrophy mediated by LPS, and proinflammatory cytokine COX-2 and IL-6 levels in murine model. Gliquidone also exhibits good anticancer activity in lung carcinoma cells. Gliquidone has antioxidant property. Gliquidone can be studied in research for type 2 diabetes and cancers .
    Gliquidone
  • HY-P0014B
    Liraglutide TFA
    35+ Cited Publications

    GLP Receptor Metabolic Disease
    Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .
    Liraglutide TFA
  • HY-N9536

    GLP Receptor Metabolic Disease
    Cinnamtannin A2, a tetrameric procyanidin, can increases GLP-1 and insulin secretion in mice. Cinnamtannin A2 could upregulate the expression of corticotrophin releasing hormone. Cinnamtannin A2 exhibits antioxidant, anti-diabetic and nephroprotective effect .
    Cinnamtannin A2
  • HY-P3616

    GCGR Metabolic Disease
    Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide is a biotin labeled glucagon-like peptide-1-(7-36). Glucagon-like peptide-1-(7-36) is a gastrointestinal peptide with antidiabetogenic activity, and can increase the release of insulin .
    Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide
  • HY-120493A

    Free Fatty Acid Receptor Metabolic Disease
    AM-6226 is a potent and orally active G protein coupled receptor 40 (GPR40) full agonist with an EC50 of 0.12 μM. AM-6226 can activate the GPR40 receptors on pancreatic β cells and enteroendocrine L cells, promote insulin secretion in a glucose-dependent manner and also increase the release of incretin hormones (GLP-1, GIP), thereby avoiding the risk of hypoglycemia. AM-6226 can be used for the research of metabolic disease, such as diabetes .
    AM-6226
  • HY-109692

    Free Fatty Acid Receptor Metabolic Disease Inflammation/Immunology
    GPR120 Agonist 5 (compound 12) is an agonist targeting GPR120 (EC50=1.2 μM). GPR120 Agonist 5 promotes the release of glucagon-like 1 (GLP-1) by binding to the GPR120 receptor, which in turn binds to its receptors on pancreatic beta cells, increasing insulin secretion and thereby lowering blood sugar levels. GPR120 Agonist 5 also helps reduce chronic low-grade inflammation, which plays an important role in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. GPR120 Agonist 5 can be used to investigate the mechanism of action of GPR120 in metabolic and inflammatory diseases .
    GPR120 Agonist 5
  • HY-B1114R

    AR-DF 26 (Standard)

    Potassium Channel Reference Standards ERK STAT NF-κB COX Interleukin Related Metabolic Disease
    Gliquidone (Standard) is the analytical standard of Gliquidone. This product is intended for research and analytical applications. Gliquidone can bind to the pancreatic β-cells and increases insulin release to regulate blood glucose levels. Gliquidone significantly decreases LPS (HY-D1056)-induced proinflammatory responses and inhibits ERK/STAT3/NF-κB phosphorylation in BV2 microglial cells. Gliquidone can suppress microgliosis, microglial hypertrophy mediated by LPS, and proinflammatory cytokine COX-2 and IL-6 levels in murine model. Gliquidone also exhibits good anticancer activity in lung carcinoma cells. Gliquidone has antioxidant property. Gliquidone can be studied in research for type 2 diabetes and cancers .
    Gliquidone (Standard)
  • HY-19002

    Adrenergic Receptor Metabolic Disease
    BRL-26830A is a β-adrenergic receptor agonist. BRL-26830A reduces body weight and increases metabolic rate in obese mouse models. BRL-26830A stimulates insulin release and significantly reduces blood glucose levels in ICR mouse models. BRL-26830A can be used to study endocrine and metabolic diseases such as obesity and diabetes .
    BRL-26830A
  • HY-120493

    Free Fatty Acid Receptor Metabolic Disease
    (rel)-AM-6226 is the relative stereoisomer of AM-6226 (HY-120493A). AM-6226 is a potent, orally active full agonist of G protein-coupled receptor 40 (GPR40) with an EC50 value of 0.12 μM. AM-6226 activates GPR40 receptors on pancreatic β-cells and enteroendocrine L-cells, promotes insulin secretion in a glucose-dependent manner, and increases the release of incretin hormones (GLP-1, GIP), thus avoiding the risk of hypoglycemia. AM-6226 can be used in the research of metabolic diseases such as diabetes .
    (rel)-AM-6226

オンラインお問い合わせ

入力情報は安全に管理されます. 必須入力項目.

タイトル

 

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

 

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: